Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.

Catherine Leroux , Elodie Vauléon (1, 2) , Marc Pracht , Yasmina Zoheir , Eveline Boucher (3) , Odile Audrain (4) , Jean-Luc Raoul (5)

1 Service de Biologie
2 IGDR - Institut de Génétique et Développement de Rennes
3 Foie, métabolismes et cancer
4 Département d'informatique médicale
5 CRLCC - CRLCC Eugène Marquis

Sorafenib, a new antiangiogenic and antiproliferative agent, is currently used for hepatocellular and renal cell carcinoma. We report here the case of a patient with two cancers, a locally advanced cancer of the piriform sinus and a hepatocellular carcinoma, who was given sorafenib. Tumor response of both cancers might suggest that sorafenib could be effective against head and neck cancer.

Mots clés: Hepatocellular carcinoma; Sorafenib; Portal vein; ENT cancer; Otorhinolaryngologic cancer

Domaines: Hépatologie et Gastroentérologie

Catherine Leroux, Elodie Vauléon, Marc Pracht, Yasmina Zoheir, Eveline Boucher, et al.. Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.. Medical oncology and tumor pharmacotherapy, 2011, 28 Suppl 1, pp.S246-9. ⟨10.1007/s12032-010-9708-8⟩. ⟨hal-00742313⟩